15 October 2021
PRESS RELEASE
It is with enthusiasm that we announce that our company BioMAdvanced Diagnostic has been able to join the France Biotech association. This membership allows the company to join a unique network of entrepreneurs sharing our daily challenges and associated experts, and who can save us substantial time and money, for instance by being able to access the knowledge base and the numerous publications of France Biotech reserved for its members. We will also be happy to be able to provide our contribution on subjects falling within our expertise.
As a reminder, BioMAdvanced Diagnostics, a BioTech/MedTech start-up from Nantes, a spinoff from the CRTI laboratory (Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM – University of Nantes) and from the University Hospital (CHU) of Nantes, which aims to offer companion molecular diagnostic tests and biomarkers in connection with the immune response of patients. On the basis of a common technological base, the first applications will concern: 1) improving the follow-up of patients who have received a kidney or lung transplant, and 2) determining the best drug to administer to patients with ulcerative colitis (UC). These tests are designed to be integrated into standard diagnostic and treatment protocols, easy to use by staff caring for targeted patients. Predictive scores are produced using algorithms based on the combination of signatures from the expression of selected genes and clinical parameters.